ACT Genomics of Taiwan Raises $8 Million for Cancer Genomics Tests

ACT Genomics Co., a Taipei company that makes cancer diagnostic tests, raised $8 million in a first round funding. Using next-gen sequencing and multiplex molecular testing platforms, ACT claims it can analyze a tumor and detect variations in more than 400 cancer-related genes. With the information, ACT can suggest the most appropriate personalized cancer treatment. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.